This approval adds to Granules India's existing 67 ANDA approvals from the US FDA, strengthening its position in regulated ...

Seizures associated with pediatric single-substance exposures are steadily increasing, according to a study presented at the ...

The company has received approval for its Abbreviated New Drug Application for Bupropion Hydrochloride extended-release ...

Bupropion hydrochloride extended-release tablets are widely prescribed for the treatment of major depressive disorder and for ...

The abbreviated new drug application (ANDA) for the product was filed with the USFDA by Granules Pharmaceuticals, Inc. (GPI), ...

Granules India's US subsidiary receives FDA approval for generic Bupropion Hydrochloride Extended-Release Tablets, expanding ...

Granules India has received USFDA approval to market a generic medication for major depressive disorder, Bupropion ...

Granules Pharmaceuticals, Inc., a 100% foreign subsidiary of Granules India received the U.S. Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA) of Bupropion ...

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) ...

The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in recent years, a new study finds.

New data shows that the number of children suffering a seizure after swallowing medications or illegal substances has doubled between 2009 and 2023 in the US. The findings were presented today ...